本帖最后由 老马 于 2013-3-13 13:43 编辑 " z* K n$ V' C0 q% U D
$ u" H! ^( p3 l
健择（吉西他滨）+顺铂+阿瓦斯汀
! [7 h( P! \0 v Gemzar +Cisplatin + Avastin! r; F, w: w7 E- V
http://annonc.oxfordjournals.org/content/21/9/1804.full
* h; v0 s. O4 M% T; u( r/ U# p4 s6 FOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
; o0 ^' G, K$ ~8 Y) ?Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
4 X6 {, h* b5 k6 e0 AResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
1 m/ g* g- S/ r; A- G& o5 ~% L: Q
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 855)
`% `0 m6 j2 I- Y* X5 _
华为网盘附件：
' i! E3 U) J, Z X' k【华为网盘】ava.JPG7 `0 n( f3 v& e' T' W6 O# u
|
显身卡
